Similar to #487, but making those classes / labels actionable in the app.
Pkg authors from highly reputable institutions like Posit, Microsoft, or the FDA who sometimes vouches for the quality of a package. However, every package developed by Hadley Wickham should not be accepted, but if it's "owned" by Posit and authored by Hadley, then it could have more weight in the risk discussion. The same goes for the FDA. There have been times where they've told practitioners to use a specific R pkg for analyses, which means they are standing by it's quality. In that case, the FDA will likely not even be the author of said package, but their could be a group of pkgs they recommend that we could accommodate in the app.
Similar to #487, but making those classes / labels actionable in the app.
Pkg authors from highly reputable institutions like Posit, Microsoft, or the FDA who sometimes vouches for the quality of a package. However, every package developed by Hadley Wickham should not be accepted, but if it's "owned" by Posit and authored by Hadley, then it could have more weight in the risk discussion. The same goes for the FDA. There have been times where they've told practitioners to use a specific R pkg for analyses, which means they are standing by it's quality. In that case, the FDA will likely not even be the author of said package, but their could be a group of pkgs they recommend that we could accommodate in the app.